Goldman Sachs Comments on E-Broker Decline (ETFC) (AMTD) (SCHW)
Get Alerts ETFC Hot Sheet
Rating Summary:
11 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
E-brokers stocks declined Thursday, with E*TRADE (NASDAQ: ETFC), TD Ameritrade (NYSE: AMTD), and Charles Schwab (NYSE: SCHW) all pressured. In the view of Goldman Sachs analyst Alexander Blostein, the issue relates to payment for order flow concerns.
"To be clear, outside of several news wires reporting on Thursday that the SEC is looking into the maker-taker model, there has not been much tangible news on the PFOF issue. However, given investor focus, we assess each E-Broker’s EPS exposure to PFOF with the caveat that this analysis involves a fair amount of assumptions (given that AMTD’s and SCHW’s disclosures are light)" said Blostein,
"* ETFC: We estimate that ETFC makes about $92mn in PFOF per year. Assuming 90% margin equates to $0.17 in EPS or 15% of 2015 consensus estimate. ETFC provides the most transparent disclosure; as per the firm’s 10K, in 2013 it made $72.5mn from PFOF, excluding flows routed to own market maker that was sold in 1Q13. Pro-forma for the sale, we estimate the annual run-rate at $92mn.
* AMTD: The company does not provide an explicit breakout of PFOF. But based on its DARTs and assuming the same relationship as observed at ETFC, we estimate $227mn in revenue contribution or $0.23 in EPS (14% of 2015 consensus estimate).
*SCHW: Based on management’s prior messaging, we estimate SCHW earns less than $100mn from PFOF, or $0.08 EPS exposure (7% of 2015 consensus EPS), below ETFC/AMTD given their deal with UBS."
For an analyst ratings summary and ratings history on E*TRADE click here. For more ratings news on E*TRADE click here.
Shares of E*TRADE closed at $22.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GXO Logistics, Inc. (GXO) Prices $1.1B Notes Offering
- AZZ, Inc. (AZZ) Announces Proposed 4M Share Offering
- HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot CommentsRelated Entities
UBS, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!